Evidence Hub

Prevalence of and risk factors for antimicrobial resistance in pneumococcal disease in southern Ontario during the PCV13 era

Shigayeva A, Coleman BL, Golden AR, Martin I, Zhanel G, Adam H, Gold WL, Kandel C et al.

Vaccine, 2026

Abstract

BACKGROUND: Pneumococcal infections are an important cause of morbidity and mortality, and a major contributor to the burden of antimicrobial resistance (AMR). Multiple factors affect AMR in pneumococci.

METHODS: The Toronto Invasive Bacterial Diseases Network (TIBDN) conducted population-based surveillance for invasive pneumococcal disease (IPD) and hospitalization due to non-bacteremic pneumococcal pneumonia (NBPP) in Toronto/Peel Region, Ontario. Laboratories reported sterile site and respiratory isolates of Streptococcus pneumoniae. Patient data were collected by chart review and patient/physician interview. Population data were from Statistics Canada. Antimicrobial susceptibility testing was performed/interpreted per Clinical and Laboratory Standards Institute guidelines and/or by prediction from whole genome sequencing (WGS). Serotyping was performed by Quellung reaction or WGS.

RESULTS: From 2014 to 2024, 3881 episodes of IPD and 887 of NBPP were identified. Resistance was most common to macrolides (31.4%, 1285/4086), tetracyclines (17.4%, 653/3756), penicillin (meningeal breakpoints: 17.2%, 749/4354), clindamycin (12.3%, 472/3823) and trimethoprim-sulfamethoxazole (12.6%, 495/3929); resistance to ceftriaxone (meningeal breakpoints) and levofloxacin was <1%. Resistance declined over time for ceftriaxone, fluoroquinolones, and erythromycin but increased for oral penicillin, tetracycline and trimethoprim-sulfamethoxazole. Non-susceptibility to ceftriaxone (meningeal…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free